SciClone Pharmaceuticals Company Profile (NASDAQ:SCLN)

About SciClone Pharmaceuticals

SciClone Pharmaceuticals logoSciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company's development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: SCLN
  • CUSIP: 80862K10
Key Metrics:
  • Previous Close: $10.49
  • 50 Day Moving Average: $11.09
  • 200 Day Moving Average: $11.62
  • Trailing P/E Ratio: 14.16
  • Foreward P/E Ratio: Infinity
  • P/E Growth: 0.00
  • Market Cap: $523.86M
  • Outstanding Shares: 49,939,000
  • Beta: 1.75
Additional Links:
Companies Related to SciClone Pharmaceuticals:

Analyst Ratings

Consensus Ratings for SciClone Pharmaceuticals (NASDAQ:SCLN) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for SciClone Pharmaceuticals (NASDAQ:SCLN)
DateFirmActionRatingPrice TargetDetails
7/9/2015BWS FinancialDowngradeHold -> SellView Rating Details
6/29/2015MLV & Co.Initiated CoverageBuyView Rating Details
1/6/2015AegisReiterated RatingPositiveView Rating Details
(Data available from 8/27/2014 forward)


Earnings History for SciClone Pharmaceuticals (NASDAQ:SCLN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216$0.20$37.90 million$39.00 millionViewN/AView Earnings Details
5/10/2016Q116$0.19$33.60 million$36.50 millionViewListenView Earnings Details
3/10/2016Q415$0.30$41.10 million$42.90 millionViewListenView Earnings Details
11/9/2015Q315$0.12$0.26$40.61 million$42.90 millionViewN/AView Earnings Details
8/10/2015Q215$0.12$0.26$37.27 million$37.90 millionViewListenView Earnings Details
5/11/2015Q414$0.03$0.17$34.00 million$33.60 millionViewListenView Earnings Details
3/11/2015Q4$0.15$0.29$38.93 million$41.43 millionViewN/AView Earnings Details
11/10/2014Q314$0.12$0.17$34.90 million$34.30 millionViewN/AView Earnings Details
8/11/2014Q214$0.10$0.20$33.40 million$32.50 millionViewListenView Earnings Details
5/12/2014Q114$0.08$0.10$32.20 million$26.60 millionViewListenView Earnings Details
3/12/2014Q314$0.15$0.08$38.30 million$32.70 millionViewListenView Earnings Details
11/12/2013Q114$0.15$0.18$39.70 million$35.20 millionViewListenView Earnings Details
8/7/2013Q2 2013$0.11$0.09$33.30 million$29.81 millionViewListenView Earnings Details
4/1/2013Q4 2012$0.12$0.04$35.30 million$33.10 millionViewListenView Earnings Details
11/9/2012Q312$0.21$0.20$43.09 million$40.70 millionViewN/AView Earnings Details
8/8/2012$0.18$0.20ViewN/AView Earnings Details
5/9/2012$0.11$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for SciClone Pharmaceuticals (NASDAQ:SCLN)
Current Year EPS Consensus Estimate: $0.72 EPS


Dividend History for SciClone Pharmaceuticals (NASDAQ:SCLN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for SciClone Pharmaceuticals (NASDAQ:SCLN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/17/2016Friedhelm BlobelCEOSell501,875$10.00$5,018,750.00View SEC Filing  
8/16/2016Wilson Wai-Shun CheungCFOSell7,802$10.62$82,857.24View SEC Filing  
3/28/2016Friedhelm BlobelCEOSell10,000$9.29$92,900.00View SEC Filing  
3/18/2016Friedhelm BlobelCEOSell10,000$9.09$90,900.00View SEC Filing  
3/7/2016Friedhelm BlobelCEOSell20,000$10.01$200,200.00View SEC Filing  
2/26/2016Friedhelm BlobelCEOSell10,000$9.98$99,800.00View SEC Filing  
1/4/2016Friedhelm BlobelCEOSell200$9.01$1,802.00View SEC Filing  
12/28/2015Friedhelm BlobelCEOSell10,000$9.17$91,700.00View SEC Filing  
12/17/2015Friedhelm BlobelCEOSell9,400$9.00$84,600.00View SEC Filing  
12/11/2015Friedhelm BlobelCEOSell600$9.00$5,400.00View SEC Filing  
12/4/2015Friedhelm BlobelCEOSell10,000$9.22$92,200.00View SEC Filing  
12/3/2015Lan XieCFOSell14,166$9.50$134,577.00View SEC Filing  
11/27/2015Friedhelm BlobelCEOSell10,000$9.24$92,400.00View SEC Filing  
11/10/2015Wilson Wai-Shun CheungCFOSell7,803$9.51$74,206.53View SEC Filing  
7/24/2015Friedhelm BlobelCEOSell10,000$9.68$96,800.00View SEC Filing  
7/17/2015Friedhelm BlobelCEOSell10,000$9.72$97,200.00View SEC Filing  
7/10/2015Friedhelm BlobelCEOSell10,000$9.21$92,100.00View SEC Filing  
7/6/2015Friedhelm BlobelCEOSell20,000$10.80$216,000.00View SEC Filing  
6/26/2015Friedhelm BlobelCEOSell10,000$9.29$92,900.00View SEC Filing  
6/19/2015Friedhelm BlobelCEOSell10,000$9.42$94,200.00View SEC Filing  
6/12/2015Chuncai MengVPSell3,007$9.23$27,754.61View SEC Filing  
6/12/2015Friedhelm BlobelCEOSell10,000$9.13$91,300.00View SEC Filing  
6/8/2015Hong ZhaoCEOSell10,000$9.23$92,300.00View SEC Filing  
6/5/2015Friedhelm BlobelCEOSell10,000$9.07$90,700.00View SEC Filing  
6/1/2015Richard J HawkinsDirectorSell4,570$9.27$42,363.90View SEC Filing  
5/29/2015Friedhelm BlobelCEOSell10,000$9.38$93,800.00View SEC Filing  
5/29/2015Richard J HawkinsDirectorSell10,430$9.32$97,207.60View SEC Filing  
5/26/2015Richard J HawkinsDirectorSell11,982$9.44$113,110.08View SEC Filing  
5/22/2015Friedhelm BlobelCEOSell10,000$9.40$94,000.00View SEC Filing  
5/18/2015Chuncai MengVPSell23,660$9.56$226,189.60View SEC Filing  
5/15/2015Lan XieCFOSell26,668$9.20$245,345.60View SEC Filing  
4/24/2015Friedhelm BlobelCEOSell10,000$9.07$90,700.00View SEC Filing  
4/10/2015Friedhelm BlobelCEOSell10,000$9.10$91,000.00View SEC Filing  
3/12/2015Wilson Wai-Shun CheungCFOSell7,803$9.07$70,773.21View SEC Filing  
12/11/2014Richard J HawkinsDirectorSell15,591$8.80$137,200.80View SEC Filing  
9/2/2014Lan XieCFOSell36,468$6.97$254,181.96View SEC Filing  
8/15/2014Nancy T ChangDirectorBuy25,040$6.00$150,240.00View SEC Filing  
5/16/2014Hong ZhaoCEOSell12,500$4.75$59,375.00View SEC Filing  
8/22/2013Min YinVPSell10,938$5.50$60,159.00View SEC Filing  
8/20/2013Min YinVPSell12,500$5.50$68,750.00View SEC Filing  
2/28/2013Friedhelm BlobelCEOBuy3,000$3.86$11,580.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for SciClone Pharmaceuticals (NASDAQ:SCLN)
News IconSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Analysts Recommendations and Insider Trading - The Independent Republic (NASDAQ:SCLN) - August 24 at 6:59 PM logoSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Reports Accounts ... - (NASDAQ:SCLN) - August 22 at 11:52 AM
News IconCerulean Pharma Inc (NASDAQ:CERU) Stock Plunged on August 18 (NASDAQ:SCLN) - August 20 at 11:18 AM logoSciclone Pharmaceuticals Inc (SCLN) President & CEO Friedhelm Blobel Sold $5 million of Stocks (NASDAQ:SCLN) - August 19 at 10:12 AM logoSCICLONE PHARMACEUTICALS INC Financials (NASDAQ:SCLN) - August 18 at 7:33 PM logoSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Trading Down – Insiders Are Selling (NASDAQ:SCLN) - August 17 at 10:19 AM logoInsiders Are Selling - SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Finance Daily (NASDAQ:SCLN) - August 16 at 7:26 PM logoETF’s with exposure to SciClone Pharmaceuticals, Inc. : August 16, 2016 (NASDAQ:SCLN) - August 16 at 7:25 PM logoSciClone Pharmaceuticals, Inc. :SCLN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 (NASDAQ:SCLN) - August 15 at 7:42 PM logoSciClone Reports Second Quarter 2016 Financial Results (NASDAQ:SCLN) - August 9 at 7:36 PM logoSciClone posts 2Q profit (NASDAQ:SCLN) - August 9 at 7:36 PM logoQ2 2016 SciClone Pharmaceuticals Inc Earnings Release - Time Not Supplied (NASDAQ:SCLN) - August 9 at 10:32 AM logoSCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Financial Statements and Exhibits (NASDAQ:SCLN) - August 3 at 7:41 PM logoTraders Actions to Focus: SciClone Pharmaceuticals, Inc. (NASDAQ ... - Street Updates (NASDAQ:SCLN) - August 1 at 11:56 AM logoSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Yearly Accounts Payable At $4.495 Millions - (NASDAQ:SCLN) - July 30 at 6:35 PM logoSciClone Pharmaceuticals To Report Second Quarter 2016 Financial Results On August 9, 2016 (NASDAQ:SCLN) - July 28 at 6:00 AM logoAccounts Payable For SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Stood At $3.267 - (NASDAQ:SCLN) - July 24 at 11:21 AM logoSciClone Pharmaceuticals Inc. (SCLN) is Trading Higher on Unusual Volume for July 21 - (NASDAQ:SCLN) - July 23 at 11:06 AM
News IconChecking in on Stock Volatility for: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Engelwood Daily (NASDAQ:SCLN) - July 22 at 7:05 PM
News IconSciclone Pharmaceuticals (NASDAQ:SCLN) Short Interest Decreased By 2.6% - Press Telegraph (NASDAQ:SCLN) - July 22 at 7:05 PM logoSciClone Pharmaceuticals Inc. (SCLN) Dropped After Strategic Review Concluded - RTT News (NASDAQ:SCLN) - July 22 at 7:05 PM
News IconTrading Action Review: Watching Unusual Volume on SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Engelwood Daily (NASDAQ:SCLN) - July 21 at 10:09 AM
News IconTraders Alert – SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Financial Breaking News (press release) (NASDAQ:SCLN) - July 21 at 10:09 AM logoYesterday Trends to Watch: Express Scripts (ESRX) , SciClone Pharmaceuticals, (SCLN) - Street Updates (NASDAQ:SCLN) - July 21 at 10:09 AM
News IconSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Spurns Buyout Offers - Scibility Media (NASDAQ:SCLN) - July 21 at 10:09 AM logoSciClone Pharmaceuticals Inc. (SCLN) Drops 20.81% on July 19 - (NASDAQ:SCLN) - July 21 at 10:09 AM logoETF’s with exposure to SciClone Pharmaceuticals, Inc. : July 20, 2016 (NASDAQ:SCLN) - July 20 at 12:52 PM logoSciClone Pharmaceuticals Inc. (SCLN) Dropped After Strategic Review Concluded (NASDAQ:SCLN) - July 20 at 10:11 AM logoSciclone Pharma (SCLN) Says No Longer in Talks with Potential Acquirers; Offers FY16 Outlook (NASDAQ:SCLN) - July 19 at 7:28 PM logoSciClone Pharmaceuticals' stock tumbles after ending discussions with acquirers (NASDAQ:SCLN) - July 19 at 7:28 PM logoSciClone Plummets After Cutting Guidance, Says It's Not Talking To Any Acquirers (NASDAQ:SCLN) - July 19 at 2:37 PM logoSciclone Pharma (SCLN) Says No Longer in Talks with Potential Acquirers; Offers FY16 Outlook - (NASDAQ:SCLN) - July 19 at 8:25 AM logo6:04 am SciClone Pharma updates FY16 EPS & revenue guidance in connection with its previous announcement that it is no longer continuing active discussions with potential acquirers (NASDAQ:SCLN) - July 19 at 6:04 AM logoSciClone Provides Update On Strategic Review Process (NASDAQ:SCLN) - July 19 at 6:00 AM logoNext Weeks Broker Price Targets For SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Fiscal Standard (NASDAQ:SCLN) - July 17 at 6:42 PM logoSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Quarterly Accounts Payable At $3.267 Millions - (NASDAQ:SCLN) - July 17 at 11:23 AM logoSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Current Analyst Ratings - Fiscal Standard (NASDAQ:SCLN) - July 15 at 12:32 PM
News IconStock on the Rise for the Quarter: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Engelwood Daily (NASDAQ:SCLN) - July 12 at 7:35 PM
News IconSciclone Pharmaceuticals (NASDAQ:SCLN) Shorted Shares Increased By 3.11% - Press Telegraph (NASDAQ:SCLN) - July 12 at 7:35 PM logoSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : July 11, 2016 (NASDAQ:SCLN) - July 11 at 9:58 AM logoSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:SCLN) - July 10 at 6:32 PM
News IconSciclone Pharmaceuticals (NASDAQ:SCLN) Shorted Shares Increased 3.11% After Market Selling - Engelwood Daily (NASDAQ:SCLN) - July 8 at 7:17 PM logoSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Updated Price Targets - FTSE News (NASDAQ:SCLN) - July 7 at 10:04 AM logoETF’s with exposure to SciClone Pharmaceuticals, Inc. : July 6, 2016 (NASDAQ:SCLN) - July 6 at 2:39 PM
News IconSome Traders Are Very Bullish on SciClone Pharmaceuticals, Inc. After Forming Bullish Wedge Up Chart Pattern - Engelwood Daily (NASDAQ:SCLN) - June 30 at 7:36 PM
News IconSciclone Pharmaceuticals (NASDAQ:SCLN) Short Interest Increased By 3.11% - Press Telegraph (NASDAQ:SCLN) - June 28 at 12:06 PM logoSciClone Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SCLN) : June 27, 2016 (NASDAQ:SCLN) - June 27 at 4:29 PM logoSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : June 24, 2016 (NASDAQ:SCLN) - June 24 at 9:01 AM logoSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Stock Momentum Hits Strength - CML News (NASDAQ:SCLN) - June 23 at 9:55 AM logoSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Analyst Price Targets For The Coming Week - Fiscal Standard (NASDAQ:SCLN) - June 20 at 6:58 PM


SciClone Pharmaceuticals (NASDAQ:SCLN) Chart for Saturday, August, 27, 2016

Last Updated on 8/27/2016 by Staff